Hexadecafluorinated zinc phthalocyanine: photodynamic properties against the EMT-6 tumour in mice and pharmacokinetics using 65Zn as a radiotracer
1996

Photodynamic Properties of Fluorinated Zinc Phthalocyanine in Tumor Treatment

Sample size: 5 publication Evidence: moderate

Author Information

Author(s): RW Boyle, J Rousseau, SV Kudrevich, MOK Obochi, JE van Lier

Primary Institution: MRC Group in the Radiation Sciences, Faculty of Medicine, Universite de Sherbrooke

Hypothesis

The study investigates the photodynamic properties and pharmacokinetics of hexadecafluorinated zinc phthalocyanine (ZnPcF16) compared to zinc phthalocyanine (ZnPc) in treating tumors.

Conclusion

Hexadecafluorinated zinc phthalocyanine shows improved solubility and pharmacokinetics, leading to better tumor response in photodynamic therapy compared to its non-fluorinated counterpart.

Supporting Evidence

  • ZnPcF16 induced complete tumor regression in 4 out of 5 mice at a dose of 5 pmol kg-1.
  • At 24 hours post-injection, ZnPcF16 showed higher tumor uptake compared to ZnPc.
  • Photodynamic therapy with ZnPcF16 resulted in significant tumor growth delay.

Takeaway

This study shows that a special type of dye can help treat tumors better because it mixes well with liquids and works faster in the body.

Methodology

The study involved synthesizing ZnPcF16, administering it to tumor-bearing mice, and evaluating its biodistribution and photodynamic effects.

Limitations

The study does not distinguish between active and inactive forms of the dye, which may affect the interpretation of photodynamic potential.

Participant Demographics

BALB/c mice, 20-25 g, with EMT-6 tumors.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication